Placenta-Derived Stem Cells for Spinal Cord Injury Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies for spinal cord injuries and related disorders, such as Myelomeningocele, have not shown substantial clinical utility due to differences between rodent and human spinal cords, and the severity or mechanism of injuries, with existing treatments failing to effectively reverse incurred damage.
Innovation Solution
The use of pre-term placenta-derived multipotent stem cells (PMSCs) and chorionic villus-derived multipotent placental stem cells (C-mpSCs) isolated from chorionic villus sampling, which are autologous and can differentiate into various cell types, are applied in utero using a biocompatible scaffold to promote tissue healing and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell therapy is applied using existing cell sources and methods, then treatment for spinal cord injury is provided, but clinical utility is not substantiated due to differences between rodent and human spinal cords
Solution Approach 1:
The patent changes the key parameter of stem cell source from traditional sources (embryonic, adult, induced pluripotent) to peritrophoblast stem cells derived from preterm placenta. This parameter change addresses the species差异性 issue by providing a human-specific cell source that can be autologously transplanted, thereby improving clinical utility while maintaining adaptability to human physiology
Solution Approach 2:
The invention enables autologous transplantation where the patient's own peritrophoblast stem cells are harvested, expanded, and retransplanted. This self-service approach eliminates immune rejection issues and reduces species差异性 barriers, improving reliability of clinical outcomes without requiring adaptation to foreign cell sources
2Object-affected harmful factors
If simple closure of spinal cord is performed in utero, then further damage is prevented, but incurred injury is not reversed
Solution Approach 1:
The patent performs stem cell transplantation during the critical window of in utero development before the spinal cord injury fully manifests. This preliminary action allows stem cells to differentiate and integrate into the developing neural tissue, preventing further damage while actively promoting reversal of incurred injury through regenerative processes
Solution Approach 2:
The peritrophoblast stem cells act as an intermediary agent that bridges the gap between simple closure (which only prevents further damage) and injury reversal. These cells differentiate into neural tissue, serving as a mediator that actively repairs incurred damage while the closure prevents additional harm
3Reliability
If autologous stem cells are used for transplantation, then immune rejection is avoided, but cell source availability is limited
Solution Approach 1:
The invention segments the placental tissue into isolated peritrophoblast stem cells that can be individually expanded in culture. This segmentation allows a small initial biopsy to yield a large number of transplantable cells, overcoming the limitation of cell source availability while maintaining autologous immune compatibility
Solution Approach 2:
The patent performs preliminary expansion of peritrophoblast stem cells in vitro before transplantation. This preliminary action multiplies the cell source from a small biopsy into sufficient quantities for therapeutic transplantation, resolving the contradiction between limited initial availability and required transplant dosage while preserving immune compatibility
Data Source
AI summary
Novel isolated stem cells derived from pre-term placental tissue and compositions comprising the stem cells are provided as well as use of the compositions for therapy, research and diagnosis. The cells and compositions are useful in treating Myelomeningocele (MCC), spina bifida (SB) or spinal cord injury or paralysis.